Last updated: September 4, 2026
Copanlisib dihydrochloride, marketed in the United States as Aliqopa by Bayer, is an intravenous phosphatidylinositol 3-kinase inhibitor approved for adults with relapsed follicular lymphoma after at least two systemic therapies. Its commercial profile is constrained by a narrow labeled population, infusion-based administration, class-wide safety concerns, and competition from oral targeted therapies and cellular therapies.
Bayer does not separately disclose Aliqopa revenue in its public financial reporting. The drug is reported within broader oncology or prescription-pharmaceutical portfolios, preventing a precise public calculation of annual product sales. The available evidence supports a mature, niche oncology product rather than a major growth asset.
What is copanlisib dihydrochloride and how does Aliqopa work?
Copanlisib is a selective inhibitor of phosphatidylinositol 3-kinase alpha and delta, or PI3K-alpha and PI3K-delta. The drug is administered by intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
| Attribute |
Copanlisib dihydrochloride |
| Brand |
Aliqopa |
| Developer and U.S. marketer |
Bayer |
| Drug class |
PI3K-alpha and PI3K-delta inhibitor |
| Route |
Intravenous infusion |
| FDA approval |
September 14, 2017 |
| Initial indication |
Relapsed follicular lymphoma after at least two systemic therapies |
| FDA pathway |
Accelerated approval |
| Principal clinical setting |
Later-line indolent B-cell non-Hodgkin lymphoma |
| Key commercial limitation |
Narrow population and infusion-center administration |
The FDA approval was based primarily on the CHRONOS-1 study, a single-arm trial in patients with relapsed or refractory indolent non-Hodgkin lymphoma. The overall response rate in the follicular lymphoma subgroup supported accelerated approval, but the absence of a randomized comparator limited the initial commercial breadth of the label.[1]
What is the FDA regulatory status of Aliqopa?
Aliqopa remains an FDA-approved treatment for relapsed follicular lymphoma after at least two systemic therapies. Its regulatory position differs from several PI3K inhibitors whose lymphoma indications were withdrawn or voluntarily removed after confirmatory-study failures, safety findings, or commercial discontinuation.
The drug carries important warnings for:
- Hyperglycemia
- Noninfectious pneumonitis
- Infections
- Hypertension
- Neutropenia
- Colitis
- Severe cutaneous reactions
These risks require laboratory monitoring, infection management, glucose control, and clinical oversight during treatment. The intravenous route also increases the operational burden relative to oral competitors.
What confirmatory evidence supports copanlisib?
The CHRONOS-3 trial evaluated copanlisib plus rituximab against placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma who had received at least one prior line of therapy. The study reported a progression-free survival benefit for the combination.[2]
That result strengthened copanlisib's clinical position in combination treatment, but the commercial impact was limited by several factors:
- The approved U.S. label remained concentrated in later-line follicular lymphoma.
- The treatment required repeated intravenous administration.
- PI3K-class safety concerns affected physician and payer perception.
- Other targeted therapies offered oral or more convenient treatment options.
- The broader lymphoma market moved toward combinations, bispecific antibodies, antibody-drug conjugates, and cellular therapies.
When does copanlisib lose exclusivity?
Copanlisib's practical exclusivity is determined by several layers:
| Exclusivity layer |
Relevance |
| FDA orphan-drug exclusivity |
The original follicular lymphoma approval received orphan-drug protection for seven years, subject to statutory conditions |
| New chemical entity exclusivity |
The drug received five years of NCE exclusivity from the initial approval |
| Patent protection |
Composition, formulation, and use patents may extend beyond regulatory exclusivity |
| Data and market exclusivity |
Combination or supplemental indications may create additional regulatory protections |
| Generic competition |
A generic applicant must address listed patents and regulatory exclusivity before launch |
The initial five-year new chemical entity period would have expired in 2022. The seven-year orphan exclusivity period associated with the 2017 approval would have extended into 2024, assuming the relevant orphan exclusivity remained operative and no regulatory change affected it.
Patent expiry cannot be stated reliably from the approval date alone. The relevant date depends on the specific patents listed for Aliqopa, patent-term adjustment, patent-term extension, terminal disclaimers, and any later-issued patents. A definitive current patent schedule requires a contemporaneous review of the FDA Orange Book and USPTO records.[3]
What is the Orange Book status of Aliqopa?
Aliqopa is an FDA-approved small-molecule product eligible for Orange Book patent listing. The Orange Book is the controlling source for listed patents and pediatric exclusivity information affecting abbreviated new drug application, or ANDA, timing.
The most commercially important legal questions are:
- Whether an active ingredient patent remains listed.
- Whether only method-of-use patents remain.
- Whether listed patents cover the approved dosing regimen.
- Whether a generic applicant can file a Paragraph IV certification.
- Whether Bayer has sued within the statutory 45-day period after receiving a Paragraph IV notice.
Public product-level revenue disclosures do not establish the number or enforceability of Aliqopa patents. Patent count alone is not a reliable measure of generic-entry risk. Composition claims generally provide stronger protection than narrow dosing or method-of-use claims.
How large is the copanlisib market?
Copanlisib operates in a specialized segment of the relapsed follicular lymphoma market. Its addressable population is narrower than that of drugs approved across multiple B-cell malignancies or earlier treatment lines.
The commercial market is affected by:
- The number of patients progressing after two or more systemic therapies.
- Treatment sequencing after anti-CD20 therapy and chemotherapy.
- Use of lenalidomide-rituximab, tazemetostat, mosunetuzumab, epcoritamab, and other targeted approaches.
- Physician willingness to use an intravenous PI3K inhibitor after class-wide safety concerns.
- Reimbursement for infusion administration and laboratory monitoring.
- Duration of treatment before progression or toxicity.
Follicular lymphoma is generally indolent, but patients with multiply relapsed disease have a high unmet need. The addressable population is clinically meaningful but small compared with broad solid-tumor indications.
How does copanlisib compare with competing follicular lymphoma drugs?
| Drug |
Company |
Administration |
Key commercial advantage |
Principal limitation |
| Copanlisib |
Bayer |
Intravenous |
Activity in relapsed follicular lymphoma; PI3K-alpha and delta inhibition |
Infusion burden and class safety concerns |
| Tazemetostat |
Ipsen |
Oral |
Oral administration and EZH2-targeted mechanism |
Biomarker and treatment-line considerations |
| Lenalidomide plus rituximab |
Bristol Myers Squibb and partners |
Oral plus infusion |
Established immunomodulatory regimen |
Myelosuppression, thrombosis, and combination burden |
| Mosunetuzumab |
Roche |
Subcutaneous after step-up dosing |
Bispecific antibody with outpatient potential |
Cytokine-release syndrome and immune-related monitoring |
| Epcoritamab |
AbbVie and Genmab |
Subcutaneous |
Broad relapsed large B-cell lymphoma positioning; expanding B-cell application |
Cytokine-release syndrome and specialized administration |
| Axicabtagene ciloleucel and other CAR-T therapies |
Multiple companies |
One-time cellular therapy |
Durable responses in selected patients |
High cost, manufacturing time, and treatment-center requirements |
Copanlisib is most competitive when physicians value a validated PI3K mechanism and want a non-cellular therapy for a patient with relapsed follicular lymphoma. It is less attractive when oral convenience, fixed-duration therapy, or durable cellular and bispecific approaches dominate treatment selection.
What is the financial trajectory for Aliqopa?
Bayer does not publish a standalone Aliqopa revenue line in its annual reports. The company reports pharmaceutical performance by broader business categories, while individual mature products may be grouped with other oncology medicines.
That disclosure structure means the financial trajectory must be assessed through commercial indicators rather than a verified product-level revenue series.
| Financial driver |
Effect on Aliqopa |
| Narrow approved population |
Limits peak sales potential |
| Later-line use |
Reduces treatment volume and increases sequencing competition |
| Intravenous administration |
Raises delivery costs and limits convenience |
| CHRONOS-3 data |
Supports continued clinical use and combination potential |
| PI3K safety concerns |
Restrains physician adoption and payer enthusiasm |
| Orphan positioning |
Supports pricing but limits volume |
| Newer oral and immune therapies |
Creates substitution pressure |
| Lack of major label expansion |
Reduces future growth potential |
| Generic timing |
Creates long-term price and share erosion risk |
Aliqopa's likely commercial trajectory is best characterized as launch, clinical validation, maturity, and gradual erosion rather than rapid expansion. The product's strongest commercial period was expected to follow the original launch and the publication of positive combination data. Later growth was limited because the drug did not become a broad front-line lymphoma therapy and did not establish a large multi-indication franchise.
Which companies are challenging copanlisib commercially?
The competitive threat does not come from a single direct substitute. It comes from several treatment classes.
Oral targeted therapies
Oral agents reduce infusion-center visits and can be integrated into community oncology practices. Tazemetostat is a direct competitive reference for relapsed follicular lymphoma, particularly where EZH2 biology and oral convenience influence treatment selection.
Bispecific antibodies
Mosunetuzumab and other CD20xCD3 bispecific antibodies compete for patients with relapsed or refractory B-cell lymphoma. Their potential for fixed-duration treatment and deep responses can displace chronic or repeated-cycle targeted therapy.
CAR-T therapy
CAR-T products are more intensive and expensive, but they compete for patients with aggressive or multiply relapsed disease. Their use is limited by eligibility, referral access, manufacturing, toxicity management, and treatment-center capacity.
Established chemoimmunotherapy
Rituximab-based combinations remain relevant in indolent lymphoma. They can compete with copanlisib where cost, familiarity, and treatment availability outweigh the advantages of a PI3K inhibitor.
What patent litigation and Paragraph IV risks affect Aliqopa?
A generic applicant seeking approval before patent expiry may submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. Bayer could then bring patent litigation within 45 days, triggering a statutory stay of ANDA approval of up to 30 months, subject to court decisions and statutory exceptions.[4]
The most important generic-entry scenarios are:
- No early ANDA challenge: Generic entry occurs after listed-patent expiry.
- Paragraph IV challenge with litigation: Approval may be delayed by the 30-month stay and subsequent court proceedings.
- Settlement: Bayer may permit a negotiated launch date before patent expiry.
- Non-infringement or invalidity finding: A generic may launch before the expected patent date.
- At-risk launch: A generic launches before final resolution and assumes damages and injunction risk.
There is no basis for treating a patent count as proof of durable exclusivity. Copanlisib's strongest protection would come from valid, enforceable composition claims. Use patents may be less effective where a generic can carve out the protected indication or dosing regimen under a section viii statement.
What manufacturing and intellectual-property barriers apply?
Copanlisib is a chemically synthesized small molecule rather than a biologic. It does not face biosimilar substitution under the Public Health Service Act. A competitor would pursue an ANDA, not a biosimilar application.
The main manufacturing barriers are:
- Reproducible synthesis of the active pharmaceutical ingredient.
- Control of the dihydrochloride salt form.
- Sterile injectable production.
- Stability and particulate control.
- Validation of the intravenous formulation.
- Compliance with current good manufacturing practice requirements.
These barriers are meaningful but usually less durable than biologic manufacturing barriers. Once a generic manufacturer establishes an equivalent injectable product and secures reliable sterile capacity, price competition can be substantial.
Is there biosimilar risk for copanlisib?
No. Copanlisib is a small-molecule drug, so its principal loss-of-exclusivity risk is generic competition through the ANDA pathway. Biosimilar competition applies to biologic products and does not govern Aliqopa.
What licensing deals support copanlisib's commercial position?
Copanlisib was developed and commercialized by Bayer. The product is not primarily known for a major external licensing transaction that would redistribute economics among several pharmaceutical companies.
The absence of a large disclosed licensing structure simplifies the commercial analysis: Bayer retains the principal economic exposure, while product performance depends on Bayer's oncology commercial organization, clinical investment, manufacturing network, and ability to defend intellectual property.
What generic launch scenarios exist for copanlisib?
The most likely sequence is:
| Scenario |
Market consequence |
| Entry after all meaningful patents expire |
Gradual price decline followed by share loss |
| One generic entrant |
Moderate price pressure; Bayer may retain some hospital and physician preference |
| Multiple injectable generics |
Faster erosion and payer-driven substitution |
| Authorized generic or settlement launch |
Earlier price competition with controlled timing |
| Narrow label carve-out |
Generic competes in unprotected uses while Bayer retains protected indication |
| Manufacturing disruption |
Slower uptake despite regulatory approval |
Because Aliqopa is an infused oncology drug, substitution may be slower than with a high-volume oral tablet. Hospitals and infusion centers evaluate supply reliability, handling, reimbursement, and clinical familiarity. The low patient volume, however, may reduce the commercial incentive for many generic manufacturers to enter.
How much revenue is exposed to copanlisib loss of exclusivity?
A precise revenue exposure figure is unavailable because Bayer does not separately report Aliqopa sales. The financial risk is therefore likely to be material at the product level but limited at Bayer's consolidated level.
Revenue exposure depends on:
- Current U.S. net sales.
- International availability and reimbursement.
- The proportion of sales generated by the original follicular lymphoma label.
- Remaining patent life.
- Number of approved generic competitors.
- Contracting and hospital purchasing behavior.
- Bayer's ability to retain share through clinical differentiation.
The product is unlikely to represent a major percentage of Bayer's total pharmaceutical revenue. Its strategic value is greater as a targeted oncology asset within a broader portfolio than as a company-wide earnings driver.
How strong is the copanlisib patent estate?
Copanlisib's patent estate should be assessed as a layered small-molecule estate rather than a biologic-style exclusivity barrier.
| Patent layer |
Expected strength |
| Active ingredient or composition claims |
Highest potential strength |
| Salt and crystalline-form claims |
Moderate to high if technically specific and difficult to design around |
| Injectable formulation claims |
Moderate, depending on claim scope |
| Manufacturing-process claims |
Variable; difficult to enforce without access to process evidence |
| Dosing and administration claims |
Variable and vulnerable to label carve-outs |
| Method-of-use claims |
Useful for protected indications but narrower than composition claims |
The business consequence is direct: a robust composition patent can delay broad generic substitution, while a portfolio dominated by narrow method or formulation claims may allow earlier competition through design-around strategies.
Key Takeaways
- Copanlisib dihydrochloride is Bayer's intravenous PI3K-alpha and PI3K-delta inhibitor marketed as Aliqopa.
- The FDA approved it in 2017 for relapsed follicular lymphoma after at least two prior systemic therapies.
- The product has a narrow later-line market and faces competition from oral targeted drugs, bispecific antibodies, CAR-T therapies, and established chemoimmunotherapy.
- Positive CHRONOS-3 data support continued clinical relevance but have not transformed Aliqopa into a broad oncology franchise.
- Bayer does not separately disclose Aliqopa revenue, so a verified product-level financial trajectory cannot be calculated from public company filings.
- The five-year NCE exclusivity period began expiring in 2022, while the original orphan exclusivity period extended into 2024, subject to the applicable statutory record.
- Generic risk depends on the current Orange Book patent list, Paragraph IV activity, patent litigation, and the strength of composition claims.
- Aliqopa has no biosimilar risk because it is a small molecule. Its primary post-exclusivity threat is ANDA-based generic competition.
- The product is a niche oncology asset with likely mature or declining commercial economics rather than a high-growth franchise.
FAQs
Is copanlisib still FDA approved?
Yes. Aliqopa remains an FDA-approved treatment for adults with relapsed follicular lymphoma after at least two systemic therapies.
Is copanlisib a chemotherapy drug?
No. Copanlisib is a targeted PI3K-alpha and PI3K-delta inhibitor. It is not a conventional cytotoxic chemotherapy.
Is Aliqopa administered orally?
No. Aliqopa is administered by intravenous infusion on a repeated schedule within each 28-day treatment cycle.
Can copanlisib be substituted automatically by a biosimilar?
No. Copanlisib is a small-molecule drug. Any direct follow-on product would generally require an ANDA and would be treated as a generic, not a biosimilar.
What is the largest commercial weakness of Aliqopa?
The largest weakness is the combination of later-line positioning, repeated intravenous administration, PI3K-class safety monitoring, and competition from newer oral, bispecific, and cellular therapies.
References
-
U.S. Food and Drug Administration. (2017). FDA approves Aliqopa for follicular lymphoma. FDA.
-
Dreyling, M., Santoro, A., Molica, S., Leppä, S., Follows, G., Lenz, G., et al. (2020). Long-term safety and efficacy of copanlisib in combination with rituximab in relapsed indolent non-Hodgkin lymphoma. The Lancet Oncology.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman Amendments and abbreviated new drug applications. FDA.
-
Bayer AG. (2023). Annual report 2023. Bayer AG.
